Journals / Medeniyet Medical Journal / 2021 / Cilt: 36 - Sayı: 4

The Clinical Impact of Tumor Grade Heterogeneity in Nonmuscle- invasive Urothelial Carcinoma of the Bladder

Kasa İnvaze Olmayan Ürotelyal Mesane Kanserinde Tümör Grade Heterojenitesinin Klinik Önemi

Pages
310–317
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our results should be verified by future studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study aimed to determine the oncological outcomes of mixed-grade tumors by comparing them with pure low-grade and high-grade tumors.
📊
Key Findings & Data:Results: A total of 369 patients (190 low, 40 mixed, and 139 high-grade) were included in our study, with a mean follow-up of 55.94±41.73 months.
💡
Conclusion & Impact:Our results should be verified by future studies.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: This study aimed to determine the oncological outcomes of mixed-grade tumors by comparing them with pure low-grade and high-grade tumors. Methods: We retrospectively reviewed the medical records of patients with primary non-muscle-invasive bladder cancer. Patients were categorized into three groups according to the histological grade of their tumors: low-grade, mixed-grade, and high-grade. Clinicopathological characteristics and oncological outcomes, such as recurrence-free survival (RFS), progression-free survival (PFS), and cancer-specific survival (CSS), were compared between the three groups. Results: A total of 369 patients (190 low, 40 mixed, and 139 high-grade) were included in our study, with a mean follow-up of 55.94±41.73 months. Patients with mixed-grade tumors had lower rates of pT1 stage diseases than those with high-grade tumors (42.5% vs. 64.0%, respectively) and higher rates than those with low-grade tumors (14.7% vs. 42.5%, respectively) (p=0.001). There was no significant difference in RFS between low-, mixed-, and high-grade tumor patients (p=0.887). Patients with mixed-grade tumors had worse PFS and CSS outcomes than those with low-grade tumors (199.84±23.22 vs. 214.94±15.92 for PFS and 202.07±19.86 vs. 233.61±9.84 for CSS, respectively) and better PFS and CSS outcomes than those with highgrade tumors (199.84±23.22 vs. 163.28±16.18 for PFS and 202.07±19.86 vs. 180.81±15.89 for CSS, respectively), although these comparisons were not statistically significant. Conclusions: Patients with mixed-grade tumors had worse PFS and CSS outcomes than patients with low-grade tumors and better PFS and CSS outcomes than patients with high-grade tumors, although these comparisons were not statistically significant. Our results should be verified by future studies.

Özet

Amaç: Çalışmamızda histolojik olarak düşük ve yüksek derecenin bir arada olduğu karma dereceli tümörlerin onkolojik sonuçlarının saf düşük dereceli ve yüksek dereceli tümörler ile karşılaştırılması amaçlandı. Yöntemler: Primer kasa invaze olmayan mesane kanserli hastaların tıbbi kayıtlarını geriye dönük olarak inceledik. Hastalar histolojik dereceye göre düşük, karma ve yüksek dereceli olmak üzere üç gruba ayrıldı. Üç grubun nükssüz sağkalım (NS), progresyonsuz sağkalım (PS) ve kansere özgü sağkalım (KSS) gibi onkolojik sonuçları ve klinikopatolojik özellikleri karşılaştırıldı. Bulgular: Ortalama 55,94±41,73 aylık takipte toplam 369 hasta (190 düşük, 40 karma ve 139 yüksek dereceli) çalışmamıza dahil edildi. pT1 evre hastalık oranı; karma dereceli tümörü olan hastalarda yüksek dereceli tümörlere göre daha düşük oranda (sırasıyla %42,5 ve %64,0) ve düşük dereceli tümörlere göre daha yüksek oranda (sırasıyla %42,5 ve %14,7) gözlendi (p=0,001). Düşük, karma ve yüksek dereceli hastalar arasında NS açısından istatistiksel olarak anlamlı bir fark yoktu (p=0,887). Karma dereceli tümörü olan hastalar, düşük dereceli tümörlere göre daha kötü PS ve KSS’ye sahipken (sırasıyla PS için 199,84±23,22'ye karşı 214,94±15,92 ve KSS için 202,07±19,86’ya karşı 233,61±9,84) yüksek dereceli tümörlere göre daha iyi PS ve KSS sonuçlarına sahipti (sırasıyla PS için 199,84±23,22’ye karşı 163,28±16,18 ve KSS için 202,07±19,86’ya karşı 180,81±15,89). Ancak bu karşılaştırmalar istatistiksel olarak anlamlı değildi. Sonuçlar: Karma dereceli tümörü olan hastalarda, düşük dereceli tümörlere göre daha kötü PS ve KSS saptanırken, yüksek dereceli tümörlere göre daha iyi PS ve KSS saptandı. Ancak bu karşılaştırmalar istatistiksel olarak anlamlı değildi. Sonuçlarımız gelecek çalışmalarla doğrulanmalıdır

🔖

Cite This Article

IPLIKCI, A., KESER, F., CULPAN, M., KIR, G., ATIS, G., YILDIRIM, A. (2022). The Clinical Impact of Tumor Grade Heterogeneity in Nonmuscle- invasive Urothelial Carcinoma of the Bladder. Medeniyet Medical Journal, Cilt: 36 - Sayı: 4, 310–317. https://ajindex.com/articles/579172

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7-33. Erratum in: CA Cancer J Clin. 2021;71:359
  2. Burger M, Catto JWF, Dalbagni G, et al. Platinum priority – review – bladder cancer epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234-41
  3. Sylvester RJ, Rodríguez O, Hernández V, et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel[Formula present. Eur Urol. 2021;79:480–8. 4. van der Kwast T, Liedberg F, Black PC, et al. International society of urological pathology expert opinion on grading of urothelia 5. Eble J, Sauter G, Epstein J, Sesterhenn I. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon, France: IARC Press; 2004
  4. Babjuk M, Burger M, Compérat EM, et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019;76:639-57
  5. Gofrit ON, Pizov G, Shapiro A, et al. Mixed high and low grade bladder tumors - Are they clinically high or low grade? J Urol. 2014;191:1693-6
  6. Brierley JD, Gospodarowicz MD, Wittekind C, editors. TNM Classification of Malignant Tumours. 8th ed. New York: Wiley-Blackwell; 2017
  7. Cheng L, Neumann RM, Nehra A, Spotts BE, Weaver AL, Bostwick DG. Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. J Urol. 2001;165:696-7
  8. Billis A, Carvalho RB, Mattos AC, et al. Tumor grade heterogeneity in urothelial bladder carcinoma: Proposal of a system using combined numbers. Scand J Urol Nephrol. 2001;35:275-9
  9. Ho P, Moran GW, Wang V, et al. The effect of tumor grade heterogeneity on recurrence in non-muscle invasive bladder cancer. Urol Oncol. 2021:S1078-1439(21)00304-5. doi: 10.1016/j.urolonc.2021.07.003. Epub ahead of print
  10. Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C. Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol. 2010;28:401-8
  11. Cordon-Cardo C. Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol. 2008;42(Suppl 218):154-65
  12. Mai KT, Flood TA, Williams P, Kos Z, Belanger EC. Mixed low- and high-grade papillary urothelial carcinoma: Histopathogenetic and clinical signific